3rd International Symposium Ovarian Cancer: Prevention, Detection and Treatment of the Disease and Its Recurrence

On May 10-11, 2012 the National Cancer Coalition is hosting its 3rd International Symposium titled "Ovarian Cancer: Prevention, Detection and Treatment of the Disease and Its Recurrence" in Pittsburgh, PA. There will be scientific sessions focusing on molecular mechanisms and personalized medicine. In addition, the public education sessions will discuss integrative therapies for women and families facing ovarian cancer.

Join experts in ovarian cancer research and treatment, as well as public health professionals, policy makers and consumer advocates to discuss current and emerging modalities for the prevention, detection and treatment of ovarian cancer and its recurrence.

For more information, contact Judy Koryak (412) 641-5418 ovarian@pitt.edu or visit the website: http://www.upci.upmc.edu"

SURVIVOR EDUCATION PROGRAM

The Future of Ovarian & Gynecologic Cancer, presented by Dr. Michael V. Seiden, MD, PhD, President and CEO of Fox Chase Cancer Center, Philadelphia, PA, to Rhonda's Club on September 12, 2011.

Click on the image above to watch the video.

Click here to download slides accompanying Dr. Michael V. Seiden's presentation.

view our calendar of events >

MEDICAL NEWS

Ovarian Cancer Advocates Troubled by FDA Decision on Avastin and Breast Cancer
Posted by the Ovarian Cancer National Alliance (OCNA)

On November 18, the Food and Drug Administration (FDA) announced that it would remove metastatic breast cancer from the label for Avastin (bevacizumab). This decision follows recommendations made in June by the FDA Oncologic Drugs Advisory Committee. Responding to today’s decision, OCNA CEO Karen Orloff Kaplan, MSW, MPH, ScD, expressed concern that the removal of metastatic breast cancer from the Avastin label could negatively affect women with ovarian cancer, for whom the drug is used off-label.  read more >>

Ovarian Cancer Patients with BRCA Mutations May Fare Better than Non-Carriers

A large, multicenter study shows that women with ovarian cancer who have mutations in the BRCA1 or BRCA2 genes have better survival rates than women who do not have such mutations. The study is also the first to provide strong evidence that ovarian cancer prognosis is better for women with BRCA2 mutations than women with BRCA1 mutations. The results were published online today in JAMA. Inherited mutations in BRCA1 and BRCA2 are the strongest known genetic risk factors for breast cancer and epithelial ovarian cancer, the most common form of ovarian cancer. To read more click here.

more resources >